Biotechnology Industry Statistics
January 2009

- 120 companies (30%) are now trading with less than 6 months of cash on hand. This represents a jump of 90% more companies that have less than 6 months cash on hand vs. 2007. (source: BIO)

- 180 companies (45%) have less than 1 year of cash remaining” This represents a jump of 65% more companies that have less than 1 year cash on hand vs. 2007. (source: BIO)

- Only 10% of the 370 public US biotech companies have positive income. (source: BIO)

- By comparison with 2007, funds raised from IPOs in 2008 fell 97% and follow-on/secondary offerings fell 56%. Total capital raised by the industry in 2008 fell by 55% vs 2007 (source: BioCentury).

- In 2006, 32 life sciences companies raised $1.7 billion through IPOs. In 2007, 41 raised $1.9 billion. In 2008, there was only one IPO in the US, which raised $5.8 million. (source: BioWorld)

- There were 19 biotech IPOs withdrawn in 2008.

- There were 6 biotech bankruptcies in 2008.

- Stock Performance in 2008:
  - All US biotech stock performance: Mean - 49%, Median -61% ;
  - Small US biotech stock performance: Mean - 51%, Median -64%;
  - Large US biotech stock performance: Mean - 26%, Median -30%, (Large defined here as >$1B Mkt Cap on Jan 1st, 2008)
  - 87% of US biotech stocks have lost value in 2008
• 26% of 350 biotech companies currently trading under $1 Billion in market cap are trading below their cash value. That is, they have more cash on hand per share than the market value of their companies. This level has gone up by 3x vs 2007. (source: BIO).

• 78% of BIO’s companies have less than 50 employees, and 9% of BIO’s companies have between 50-100 employees.

• More than 80 companies laid off over 5,000 employees in 2008, and 34 biotech companies laid-off 10% or more of their workforce since September, 2008. (source: BioWorld, BIO)

• From September 2008 to January 2009, over 24 companies shelved promising drug development programs in a number of therapeutic areas including: Alzheimer’s, Multiple Sclerosis, diabetes and various cancers (source: BioCentury)

• The biosciences sector pays, on average, 68% higher salaries than the average private-sector job. The average annual wage of the bioscience worker is approximately $71,000 as compared with an average annual wage of $42,000 for the total private sector. (source: Battelle)

• The total employment in the biosciences in the U.S. reached 1.3 million in 2006, up from 1.2 million in 2004, with bioscience workers found in all 50 states and Puerto Rico. (source: Battelle)

• The U.S. biotechnology industry is very R&D-intensive with $30 billion in 2007 invested in research for new therapies and cures. There are currently more than 400 biotech drug products and vaccines currently in clinical trials targeting more than 200 diseases including various cancers, Alzheimer’s disease, heart disease, diabetes, multiple sclerosis, AIDS and arthritis. (source: E&Y)